TapewireFind a company

person · Reporting owner

Lloyd George W.

Disclosed activity across 1 company

Tapewire entity
71137
SEC CIK
0001814899

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Royalty Pharma plcRPRX · Entity 3100EVP, Investments & CLODecember 17, 2025December 19, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Royalty Pharma plc

Report date December 17, 2025 · Filed December 19, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Class A Ordinary SharesSEC Table I · non-derivativeIndirectBy GWL 2014 G, LLC30,654 Reported balance After 2025-12-17 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 1 · 2025-12-17 · Sale · Disposed 79,346 · Balance 30,654

F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Class A Ordinary SharesSEC Table I · non-derivativeIndirectBy GWL 2014 G, LLC0 Reported balance After 2025-12-18 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2025-12-18 · Sale · Disposed 30,654 · Balance 0

F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.

F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Class A Ordinary SharesSEC Table I · non-derivativeIndirectBy GWL 2013 NG, LLC495,860 Reported balance Holding disclosure · report date 2025-12-17 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 495,860

Class A Ordinary SharesSEC Table I · non-derivativeIndirectBy IRA273,960 Reported balance Holding disclosure · report date 2025-12-17 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 273,960

Class A Ordinary SharesSEC Table I · non-derivativeIndirectBy GWL 2023 G HoldCo LLC6,084 Reported balance Holding disclosure · report date 2025-12-17 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 6,084

Class A Ordinary SharesSEC Table I · non-derivativeIndirectBy Spouse4,011.19 Reported balance Holding disclosure · report date 2025-12-17 · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · Balance 4,011.19

Filing footnotes · ownership attribution and instrument terms

F1: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.

F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 18, 2025 Filed Dec 19, 2025 17:24 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 30,654 $38.50 $1,180,053.32
Disclosure

SEC source: 0001814899-25-000010 · wk-form4_1766183086.xml · nonDerivative · entry 2

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Plan reported

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 0

F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.67 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
December 17, 2025 Filed Dec 19, 2025 17:24 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 79,346 $38.57 $3,060,280.00
Disclosure

SEC source: 0001814899-25-000010 · wk-form4_1766183086.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Plan reported

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 30,654

F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.31 to $38.87 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
December 03, 2025 Filed Dec 5, 2025 17:01 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 110,000 $39.77 $4,375,008.00
Disclosure

SEC source: 0001814899-25-000008 · wk-form4_1764972084.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Plan reported

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 110,000

F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.36 to $40.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 19, 2025 Filed Nov 21, 2025 16:55 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 230 $39.03 $8,977.61
Disclosure

SEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 8

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.79 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 19, 2025 Filed Nov 21, 2025 16:55 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 2,770 $38.29 $106,051.67
Disclosure

SEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 7

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 230

F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.79 to $38.78 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 19, 2025 Filed Nov 21, 2025 16:55 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 2,470 $39.01 $96,346.55
Disclosure

SEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 6

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Plan reported

Ownership: Indirect · By GWL 2021 G, LLC

Disclosed balance after: 0

F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 19, 2025 Filed Nov 21, 2025 16:55 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 25,530 $38.28 $977,260.32
Disclosure

SEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 5

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Plan reported

Ownership: Indirect · By GWL 2021 G, LLC

Disclosed balance after: 2,470

F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 19, 2025 Filed Nov 21, 2025 16:55 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 4,599 $39.01 $179,393.65
Disclosure

SEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 4

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Plan reported

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 0

F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 19, 2025 Filed Nov 21, 2025 16:55 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 47,401 $38.28 $1,814,448.66
Disclosure

SEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 3

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Plan reported

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 4,599

F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 19, 2025 Filed Nov 21, 2025 16:55 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 4,628 $39.01 $180,527.64
Disclosure

SEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 2

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Plan reported

Ownership: Indirect · By GWL 2023 G HoldCo LLC

Disclosed balance after: 6,084

F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.77 to $39.34 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 19, 2025 Filed Nov 21, 2025 16:55 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 47,798 $38.28 $1,829,650.08
Disclosure

SEC source: 0001814899-25-000006 · wk-form4_1763762134.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Plan reported

Ownership: Indirect · By GWL 2023 G HoldCo LLC

Disclosed balance after: 10,712

F1 · kind: All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 20, 2025.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.76 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 05, 2025 Filed Nov 7, 2025 16:18 UTC Royalty Pharma plc RPRX · Entity 3100 GrantClass A Ordinary Shares 6,168 $0.00 $0.00
Disclosure

SEC source: 0001814899-25-000003 · wk-form4_1762550308.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2023 G HoldCo LLC

Disclosed balance after: 58,510

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Read SEC document
August 08, 2025 Filed Aug 8, 2025 16:56 UTC Royalty Pharma plc RPRX · Entity 3100 GiftLP interests in RPI US Partners 2019, LP · Derivative 8,500 $0.00 $0.00
Disclosure

SEC source: 0001802768-25-000103 · wk-form4_1754686616.xml · derivative · entry 9

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 85,000 shares

Expires not disclosed

F2 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Amended and Restated Exchange Agreement. No additional value will be paid by the Reporting Person in connection with an exchange.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

Read SEC document
August 06, 2025 Filed Aug 8, 2025 16:56 UTC Royalty Pharma plc RPRX · Entity 3100 GrantClass A Ordinary Shares 3,696 $0.00 $0.00
Disclosure

SEC source: 0001802768-25-000103 · wk-form4_1754686616.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2023 G HoldCo LLC

Disclosed balance after: 52,342

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Read SEC document
May 16, 2025 Filed May 20, 2025 16:51 UTC Royalty Pharma plc RPRX · Entity 3100 GrantClass E Ordinary Shares · Derivative 1,944,471 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001802768-25-000065 · wk-form4_1747774253.xml · derivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote (1)(2)

Disclosed balance after: 1,944,471

Underlying: Class A Ordinary Shares · 1,944,471 shares

Expires not disclosed

F1 · shares: Reflects the exempt indirect acquisition by the Reporting Person pursuant to Rule 16b-3 of Class E ordinary shares ("Class E Shares") of Royalty Pharma Holdings Ltd ("RPH") in connection with the consummation of the transactions contemplated by the Membership Interests Purchase Agreement, dated as of January 10, 2025 (as many be amended from time to time, the "Purchase Agreement") between RPH, Royalty Pharma, LLC, RP Management, LLC, the Issuer and certain other parties thereto.

F2 · derivative.exercise_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

F2 · derivative.expiration_date: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

F2 · derivative.underlying_shares: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

F2 · balance_after: Each Class E share will vest in installments over a 9-year period. Once vested, the Class E Shares may be converted at any time into an equivalent number of Class B ordinary shares of RPH ("Class B Shares") on a one-for-one basis, and there is no expiration date for such conversion. Each Class B Share may be converted at any time into an equivalent number of Class A ordinary shares of the Issuer on a one-for-one basis and there is no expiration date for such conversion.

Read SEC document
May 08, 2025 Filed May 9, 2025 17:15 UTC Royalty Pharma plc RPRX · Entity 3100 GrantClass A Ordinary Shares 48,646 $0.00 $0.00
Disclosure

SEC source: 0001802768-25-000037 · wk-form4_1746825335.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2023 G HoldCo LLC

Disclosed balance after: 48,646

F1 · shares: Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.

Read SEC document
August 12, 2024 Filed Aug 12, 2024 19:19 UTC Royalty Pharma plc RPRX · Entity 3100 GiftLP interests in RPI US Partners 2019, LP · Derivative 7,920 $0.00 $0.00
Disclosure

SEC source: 0001802768-24-000049 · wk-form4_1723504736.xml · derivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 79,200 shares

Expires not disclosed

F1 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.

F2 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

Read SEC document
November 13, 2023 Filed Nov 14, 2023 19:35 UTC Royalty Pharma plc RPRX · Entity 3100 ConversionLP interests in RPI US Partners 2019, LP · Derivative 10,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001802768-23-000032 · wk-form4_1700008499.xml · derivative · entry 8

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 162,680

Underlying: Class A Ordinary Shares · 100,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,096 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.

Read SEC document
November 13, 2023 Filed Nov 14, 2023 19:35 UTC Royalty Pharma plc RPRX · Entity 3100 ConversionLP interests in RPI US Partners 2019, LP · Derivative 5,000 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001802768-23-000032 · wk-form4_1700008499.xml · derivative · entry 7

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 245,299

Underlying: Class A Ordinary Shares · 50,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,096 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.

Read SEC document
November 13, 2023 Filed Nov 14, 2023 19:35 UTC Royalty Pharma plc RPRX · Entity 3100 ConversionClass A Ordinary Shares 100,000 $0.00 $0.00
Disclosure

SEC source: 0001802768-23-000032 · wk-form4_1700008499.xml · nonDerivative · entry 2

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 220,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,096 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.

Read SEC document
November 13, 2023 Filed Nov 14, 2023 19:35 UTC Royalty Pharma plc RPRX · Entity 3100 ConversionClass A Ordinary Shares 50,000 $0.00 $0.00
Disclosure

SEC source: 0001802768-23-000032 · wk-form4_1700008499.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 80,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F1 · price: These Class A Ordinary Shares will be received by the Reporting Person in exchange for limited partnership interests in RPI US Partners 2019, LP ("RPI US LP"). Each limited partnership interest in RPI US LP ("RPI US LP Interest") will be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. This exchange will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with the exchange.

F2 · balance_after: The Reporting Person has agreed to retain and not sell Class A Ordinary Shares and RPI US LP Interests convertible into Class A Ordinary Shares representing approximately 4,573,096 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.

Read SEC document
August 08, 2023 Filed Aug 8, 2023 17:36 UTC Royalty Pharma plc RPRX · Entity 3100 GiftLP interests in RPI US Partners 2019, LP · Derivative 5,555 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-045063 · doc4.xml · derivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 55,550 shares

Expires not disclosed

F1 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.

F2 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold.

F3 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F3 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

Read SEC document
June 06, 2023 Filed Jun 6, 2023 17:07 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 79,099 $33.82 $2,674,795.96
Disclosure

SEC source: 0001209191-23-034792 · doc4.xml · nonDerivative · entry 4

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 30,000

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.02 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 05, 2023 Filed Jun 6, 2023 17:07 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 19,215 $33.54 $644,446.12
Disclosure

SEC source: 0001209191-23-034792 · doc4.xml · nonDerivative · entry 3

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 109,099

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $33.69 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 02, 2023 Filed Jun 6, 2023 17:07 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 1,686 $33.54 $56,542.03
Disclosure

SEC source: 0001209191-23-034792 · doc4.xml · nonDerivative · entry 2

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 128,314

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.53 to $33.55 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
June 02, 2023 Filed Jun 6, 2023 17:07 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 92,221 $33.65 $3,102,803.21
Disclosure

SEC source: 0001209191-23-034792 · doc4.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 120,000

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.51 to $33.80 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 29, 2023 Filed Mar 30, 2023 17:52 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 12,779 $37.03 $473,165.48
Disclosure

SEC source: 0001209191-23-021648 · doc4.xml · nonDerivative · entry 2

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 212,221

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.75 to $37.31 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
March 28, 2023 Filed Mar 30, 2023 17:52 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 100,000 $37.06 $3,706,130.00
Disclosure

SEC source: 0001209191-23-021648 · doc4.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: No plan indicated

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 225,000

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.90 to $37.19 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 23, 2023 Filed Feb 27, 2023 19:14 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 25,000 $37.27 $931,657.50
Disclosure

SEC source: 0001209191-23-013398 · doc4.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 325,000

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.19 to $37.37 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 22, 2022 Filed Nov 22, 2022 17:29 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 1,900 $43.14 $81,969.04
Disclosure

SEC source: 0001209191-22-058450 · doc4.xml · nonDerivative · entry 4

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 350,000

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.30 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 22, 2022 Filed Nov 22, 2022 17:29 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 14,469 $43.19 $624,878.49
Disclosure

SEC source: 0001209191-22-058450 · doc4.xml · nonDerivative · entry 3

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 130,000

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.30 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 21, 2022 Filed Nov 22, 2022 17:29 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 3,100 $43.11 $133,637.90
Disclosure

SEC source: 0001209191-22-058450 · doc4.xml · nonDerivative · entry 2

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 351,900

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 21, 2022 Filed Nov 22, 2022 17:29 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 20,531 $43.11 $885,081.14
Disclosure

SEC source: 0001209191-22-058450 · doc4.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 144,469

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 10, 2022 Filed Nov 14, 2022 17:13 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 25,000 $43.85 $1,096,287.50
Disclosure

SEC source: 0001209191-22-056677 · doc4.xml · nonDerivative · entry 2

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 355,000

F1 · shares: Class A Ordinary Shares sold pursuant to a 10b5-1 plan.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.65 to $43.94 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 10, 2022 Filed Nov 14, 2022 17:13 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 25,000 $43.85 $1,096,325.00
Disclosure

SEC source: 0001209191-22-056677 · doc4.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 165,000

F1 · shares: Class A Ordinary Shares sold pursuant to a 10b5-1 plan.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.64 to $43.95 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 12, 2022 Filed Nov 14, 2022 17:13 UTC Royalty Pharma plc RPRX · Entity 3100 GiftLP interests in RPI US Partners 2019, LP · Derivative 5,889 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-056677 · doc4.xml · derivative · entry 7

Lloyd George W. · CIK 0001814899 · EVP, Investments & CLO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Ordinary Shares · 58,890 shares

Expires not disclosed

F4 · derivative.exercise_price: No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.

F5 · kind: The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold.

F6 · derivative.exercise_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

F6 · derivative.expiration_date: Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.

Read SEC document
August 10, 2022 Filed Aug 11, 2022 17:02 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 8,995 $43.93 $395,108.07
Disclosure

SEC source: 0001209191-22-045451 · doc4.xml · nonDerivative · entry 2

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 201,114

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.90 to $44.01 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
August 09, 2022 Filed Aug 11, 2022 17:02 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 11,859 $43.92 $520,801.03
Disclosure

SEC source: 0001209191-22-045451 · doc4.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 210,109

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.90 to $43.95 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 28, 2022 Filed Aug 1, 2022 17:01 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 4,046 $43.97 $177,892.91
Disclosure

SEC source: 0001209191-22-043689 · doc4.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 221,968

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.91 to $44.01 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 27, 2022 Filed Jul 27, 2022 18:20 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 100 $43.90 $4,390.00
Disclosure

SEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 6

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 226,014

Read SEC document
July 27, 2022 Filed Jul 27, 2022 18:20 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 25,000 $43.76 $1,094,055.00
Disclosure

SEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 5

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 380,000

F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.70 to $43.89 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 26, 2022 Filed Jul 27, 2022 18:20 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 13,886 $43.12 $598,824.03
Disclosure

SEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 4

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 226,114

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.93 to $43.35 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 26, 2022 Filed Jul 27, 2022 18:20 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 5,443 $43.03 $234,222.63
Disclosure

SEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 3

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 405,000

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.91 to $43.13 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 25, 2022 Filed Jul 27, 2022 18:20 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 11,114 $42.98 $477,641.93
Disclosure

SEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 2

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2020 G, LLC

Disclosed balance after: 228,886

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.90 to $43.17 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
July 25, 2022 Filed Jul 27, 2022 18:20 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 19,557 $42.90 $839,065.71
Disclosure

SEC source: 0001209191-22-043286 · doc4.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 410,443

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.72 to $43.16 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 27, 2022 Filed May 31, 2022 17:19 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 13,974 $40.77 $569,753.52
Disclosure

SEC source: 0001209191-22-032900 · doc4.xml · nonDerivative · entry 2

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 430,000

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.67 to $40.89 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 26, 2022 Filed May 31, 2022 17:19 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 86,026 $40.21 $3,459,337.73
Disclosure

SEC source: 0001209191-22-032900 · doc4.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 443,974

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.26 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
May 23, 2022 Filed May 25, 2022 17:10 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 100,000 $40.27 $4,026,770.00
Disclosure

SEC source: 0001209191-22-031924 · doc4.xml · nonDerivative · entry 1

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 530,000

F1 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.80 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 17, 2021 Filed Nov 18, 2021 19:18 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 84,148 $42.39 $3,566,831.76
Disclosure

SEC source: 0001209191-21-065639 · doc4.xml · nonDerivative · entry 4

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 630,000

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.92 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
November 16, 2021 Filed Nov 18, 2021 19:18 UTC Royalty Pharma plc RPRX · Entity 3100 SaleClass A Ordinary Shares 65,852 $42.12 $2,773,659.90
Disclosure

SEC source: 0001209191-21-065639 · doc4.xml · nonDerivative · entry 3

Lloyd George W. · CIK 0001814899 · EVP, Investments & GC

10b5-1 filing: Not disclosed

Ownership: Indirect · By GWL 2014 G, LLC

Disclosed balance after: 714,148

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.29 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.